RH5.1-CyRPA-Ripr antigen combination vaccine shows little improvement over RH5.1 in a preclinical setting.

MLA

Healer, Julie, et al. “RH5.1-CyRPA-Ripr Antigen Combination Vaccine Shows Little Improvement over RH5.1 in a Preclinical Setting.” Frontiers in Cellular and Infection Microbiology, vol. 12, Dec. 2022, p. 1049065. EBSCOhost, https://doi.org/10.3389/fcimb.2022.1049065.

APA

Healer, J., Thompson, J. K., Mackwell, K. L., Browne, C. D., Seager, B. A., Ngo, A., Lowes, K. N., Silk, S. E., Pulido, D., King, L. D. W., Christen, J. M., Noe, A. R., Kotraiah, V., Masendycz, P. J., Rajagopalan, R., Lucas, L., Stanford, M. M., Soisson, L., Diggs, C., … Cowman, A. F. (2022). RH5.1-CyRPA-Ripr antigen combination vaccine shows little improvement over RH5.1 in a preclinical setting. Frontiers in Cellular and Infection Microbiology, 12, 1049065. https://doi.org/10.3389/fcimb.2022.1049065

Chicago

Healer, Julie, Jennifer K Thompson, Karen L Mackwell, Cecille D Browne, Benjamin A Seager, Anna Ngo, Kym N Lowes, et al. 2022. “RH5.1-CyRPA-Ripr Antigen Combination Vaccine Shows Little Improvement over RH5.1 in a Preclinical Setting.” Frontiers in Cellular and Infection Microbiology 12 (December): 1049065. doi:10.3389/fcimb.2022.1049065.